30-Oct-2026 08:06:42

SUNPHARMA : GETS US FDA APPROVAL FOR ILUMYA IN PSORIATIC ARTHRITIS

• US FDA approved supplemental Biologics License Application for ILUMYA (tildrakizumab-asmn) for adults with active psoriatic arthritis (PsA) • IL-23 inhibitor approved exclusively for healthcare provider-administered treatment, an option for patients unable to self-administer • Expands ILUMYA beyond moderate-to-severe plaque psoriasis, approved by FDA in 2018 • Approval supported by Phase 3 INSPIRE-1 and INSPIRE-2 studies evaluating efficacy and safety after two doses at 24 weeks • No new safety signals identified in the INSPIRE studies; safety profile consistent with existing data • Approximately 2.4 million Americans live with psoriatic arthritis

Sun Pharmaceutical Industries Limited

← Back to feed